Recent

% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

dooom.booom 58 posts  |  Last Activity: May 14, 2015 11:52 AM Member since: Mar 12, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    What are the

    by shoenfield May 14, 2015 9:44 AM
    dooom.booom dooom.booom May 14, 2015 11:52 AM Flag

    we are not here for e
    earnings !! this will be Profitable by 2016 this is sure ! we expect more a big deal after R.S on Tel Aviv S.E !! we are on standby modus for a Big Pop

    Sentiment: Strong Buy

  • blrx shares trading at penny Stock Level at Tel Aviv S.E after R.S ( only on Tel Aviv ) we See Higher share price this is sure !!!

    Sentiment: Strong Buy

  • Reply to

    Set up before Big Run @ $2 !!

    by dooom.booom May 7, 2015 1:37 PM
    dooom.booom dooom.booom May 8, 2015 2:45 PM Flag

    Every buy under $2 is a GIFT buy and hold on the next Weeks you Double or Triple your Investment

  • strong Weeks ahead !! easy a 300 -500 Million Dollar Baby !!

    Sentiment: Strong Buy

  • dooom.booom dooom.booom May 5, 2015 12:04 PM Flag

    igor boy you are wrong

  • HAMPTON, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that it will present results from a recent pig study evaluating the effect of its Bioabsorbable Cardiac Matrix (BCM) on the mechanics of the heart following a heart attack. The results will be presented at the Clinical Forum of the European Society of Cardiology's Heart Failure 2015/2nd World Congress on Acute Heart Failure, being held in Seville, Spain from May 23 - May 26, 2015. The poster details are as follows:

    Title: Intracoronary artery deployment of a bioabsorbable cardiac matrix (BCM) alginate device improves mechanics of the infarct region in pigs

    Date: Saturday, May 23, 2015

    Session: Clinical Forum

    Time: 8:30am CET

    Presenter: Martin D. Meglasson, Ph.D., Chief Scientific Officer, Bellerophon Therapeutics

    Related Quotes
    BLPH
    8.45
    -1.52%
    Bellerophon Therapeutics LLC Watchlist
    8.45-0.13(-1.52%)
    NASDAQ10:57 AM EDT

    BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online 7 days ago
    BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online 22 days ago
    More
    About BCM

    BCM is an injectable device currently undergoing a double-blind, placebo controlled trial (PRESERVATION-1) for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (AMI), commonly known as a heart attack. The trial, which completed enrollment in December 2014 and is expected to report top-line results in mid-2015 following a six month evaluation period for all patients, is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in United States.

    More than 1.9 million patients in the United States and European Union suffer a heart attack each year, of which approximately 35-40% develop congestive heart failure within five years of the event. Bellerophon Therapeutics' BCM is a liquid medical device that is intended to prevent congestive heart failure after a heart attack. BCM is administered through an injection into the coronary artery, leading to the damaged area of the heart, after an AMI. The injection is made during a minimally invasive procedure called percutaneous coronary intervention (PCI), a procedure which is commonly used when opening up cardiac blood vessels in patients requiring a stent.

    Once BCM is deployed, it flows into damaged heart muscle where it forms a gel which acts as a protective meshwork, or scaffold, within the wall of the heart's left ventricle. This flexible scaffold provides physical support to the heart wall and prevents further damage, while the heart heals, after the AMI. BCM is bioabsorbable and eliminated from the body after the heart heals. Bellerophon has an exclusive worldwide license to BCM from BioLineRx Ltd.

    Sentiment: Strong Buy

  • BL -8040 is a potential new treatment for AML (continuing unmet medical need) and Stem Cell this is a Blockbuster Drug !!

  • Reply to

    Anyone adding at these levels...

    by watach Apr 30, 2015 9:42 AM
    dooom.booom dooom.booom May 1, 2015 12:06 PM Flag

    more likely $35 !

  • Reply to

    reversed split poll on mays end

    by igor_tregubov Apr 28, 2015 7:39 AM
    dooom.booom dooom.booom Apr 28, 2015 8:07 AM Flag

    reverse share split is implemented, each ADS will represent one ordinary share, par value NIS 0.10, but there will be no effect on the number of ADSs held by any owner of ADSs.

  • add Whats u can

    Sentiment: Strong Buy

  • dooom.booom dooom.booom Apr 25, 2015 11:39 AM Flag

    read facts !

  • Reply to

    Blrx is still Too high

    by classshopper Apr 21, 2015 2:34 PM
    dooom.booom dooom.booom Apr 24, 2015 3:58 PM Flag

    your momy is slow blowing

  • Adam Feuerstein in not a Analyst or anything else ***Adam Feuerstein mybe an expert of Beer and Wine and ( animal ) Dog research but he knows nothing about Biotech he receive his articles from ( John Tucker )!!! Adam hides behind armor of being a Journalist. he is the servant of the Hedge Fund devils that play the retail investors daily ** Adam Feuerstein is absolutely a tool of the short sellers in biotech. everything he writes comes from them he scare Investors with his Lie´s with his article based on no background later he came out with ethical aspect and more more garbage !! here is another example a self called analyst Adam Feuerstein !! He came out with a article last year from a 25 years old study from a family drugmaker is in "race" to get 3,4-Dap approved before $CPRX -- Jacobus study says it's only in phase II the last 25 years !! ( It won't be hard to find out why it's only in Phase II despite 25 year history !! ) only to remember nothing is for Free !! on goin Phase 2 Study's are not for Free !!! Jacobus need about 25 - 28 Million Dollar for the Phase 2 & Phase 3 Study's !! Study's from Jacobus says their compound is not safe !! this is one of the BIG reason why they are 25 year in Phase 1 b- 2 ! Jacobus received some time WARNING Letters from FDA !! FDA planed to re visit Jacobus 2014 but it BURN *** However **** The FDA personnel carry and periodically employ Geiger counters during their manufacturing facility inspections at Jacobus Pharma *** Firdapse is a Approved drug In Europe and in sales ** Catalyst Pharmaceuticals Partners licensed the North American rights from Biomarin's drug for LEMS *** The FDA granted Firdapse for Orphan drug Status !! Firdapse is in Phase 3 *** Orphan drug status means 7 Years of exclusivity rights *** the growing sales from every quarter from Firdapse from Biomarin $BMRN speak for itself ** Firdapse will be Approved in U.S soon ** Reframing the Catalyst-Jacobus Debate Following up on the recent brushfire debate on Catalyst (Firdapse) and Jacobus (compounded amifampridine), below we highlight data points that may add valuable perspective to investors focused on the LEMS space as the contemplate the true extent of this “competition.” View from Jacobus: manufacturing in a black box. We recently scheduled a call with Jacobus Pharmaceuticals (private) in order to better understand its business model, clinical plan, regulatory strategy, compounding quality control, manufacturing capability and patient outreach. After having first scheduled a time to speak with us, on further reflection, the company’s management cancelled the call, guiding that relevant and sufficient information about Jacobus is already accessible in the public domain. Following their guidance, we redirected our attention to some of the only available sources of information on Jacobus: FDA inspection reports (Form 483) of the company’s Industrial Research Laboratory Building (Schalks Crossing Road, Plainsboro, NJ) from 2011 and 2012. The reports paint a colorful picture of the equipment, quality control, production, and storage at the Jacobus facility, where Dapsone (leprosy tx) and 4-Aminosalicylic acid USP (tuberculosis tx) are also manufactured. The following are representative observations quoted in the report: (a) “procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established and followed”; (b) “there is failure to thoroughly investigate batches that do not meet specification”; (c) “containers used in the production of drug products are not identified at all times”; (d) “facilities used in the manufacturing and storage of components, API, and in-process materials are inadequate”; (e) “equipment used in manufacturing of drug products are not maintained in a state of repair”. The reports also containSchalks Crossing Road. Constructed by the Industrial Nuclear Reactor Laboratories, a consortium of major companies, the conical dome is 87 feet high and made of 18-inch-thick concrete clad in aluminum. It housed a laboratory for low-level atomic research (emphasis added). The reactor became obsolete and was decontaminated, and ownership reverted to the Walker-Gordon Laboratory Company. Today, it houses the offices of Walker-Gordon and the laboratories of Jacobus Pharmaceuticals. (emphasis added). At this time we are unable to ascertain if and how this could affect more stringent manufacturing quality and safety checks from a regulatory point of view, or whether FDA personnel carry and periodically employ Geiger counters during their manufacturing facility inspections at Jacobus Pharma

  • blrx Pipeline worth 1 Billion

    Sentiment: Strong Buy

  • Big Run up expected very soon! !

    Sentiment: Strong Buy

  • Big Run up expected very soon !!

    Sentiment: Strong Buy

  • dooom.booom dooom.booom Apr 16, 2015 10:41 AM Flag

    Pipeline worth
    10
    Times more than current share price ! really not pumping !!

    Sentiment: Strong Buy

  • sounds like a Big Deal

    Sentiment: Strong Buy

  • interesting Move from Big Pharma MYLAN !! something is brewing !!! BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma last Year /// Drug Maker Perrigo bought Omega Pharma $4.5 Billion Deal /// NOW Mylan's Move to Acquire Perrigo a Prescription for Success !! Jerusalem, December 23, 2014 – BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has entered into an exclusive out-licensing agreement with Omega Pharma, one of the largest OTC healthcare companies in Europe, for the rights to BioLineRx’s BL-5010, a novel product for the non-surgical removal of benign skin lesions, for OTC indications in the territory of Europe, Australia and additional selected countries. BioLineRx will retain the rights to BL-5010 in the United States and the rest of the world. This licensing agreement significantly accelerates the pathway to commercialization for this asset, with the first OTC products expected to enter the market in 2016.
    Under the terms of the agreement, Omega Pharma will be responsible for all development activities required to obtain regulatory approval in the licensed territory for at least two OTC indications. In addition, Omega Pharma will sponsor and manufacture the product in the relevant regions, and will have exclusive responsibility for commercialization.

    Sentiment: Strong Buy

IMUC
0.47-0.02(-3.09%)May 22 4:03 PMEDT